BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $18.55, but opened at $17.77. BridgeBio Pharma shares last traded at $15.94, with a volume of 3,872,165 shares changing hands.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on the stock. Cowen started coverage on shares of BridgeBio Pharma in a research report on Monday, February 6th. They issued an “outperform” rating on the stock. Bank of America lifted their price objective on shares of BridgeBio Pharma from $15.00 to $18.00 in a research note on Tuesday. SVB Leerink dropped their target price on shares of BridgeBio Pharma from $23.00 to $19.00 and set an “outperform” rating on the stock in a research report on Monday, January 23rd. Cowen started coverage on shares of BridgeBio Pharma in a research report on Monday, February 6th. They issued an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. raised their price target on shares of BridgeBio Pharma from $18.00 to $23.00 and gave the stock an “overweight” rating in a report on Tuesday. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, BridgeBio Pharma has an average rating of “Buy” and an average price target of $23.14.
BridgeBio Pharma Stock Down 5.9 %
The stock’s 50-day moving average is $10.52 and its 200-day moving average is $10.13. The firm has a market cap of $2.34 billion, a P/E ratio of -4.72 and a beta of 0.63.
Insider Buying and Selling at BridgeBio Pharma
Hedge Funds Weigh In On BridgeBio Pharma
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of BridgeBio Pharma by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 10,004,271 shares of the company’s stock valued at $99,442,000 after buying an additional 108,734 shares during the last quarter. Laurion Capital Management LP increased its position in shares of BridgeBio Pharma by 9.8% in the fourth quarter. Laurion Capital Management LP now owns 2,223,254 shares of the company’s stock worth $16,941,000 after purchasing an additional 198,614 shares during the period. Geode Capital Management LLC increased its position in shares of BridgeBio Pharma by 5.2% in the fourth quarter. Geode Capital Management LLC now owns 2,065,907 shares of the company’s stock worth $15,742,000 after purchasing an additional 102,030 shares during the period. Renaissance Technologies LLC grew its position in BridgeBio Pharma by 230.7% in the third quarter. Renaissance Technologies LLC now owns 1,366,746 shares of the company’s stock valued at $13,585,000 after acquiring an additional 953,500 shares during the last quarter. Finally, Barclays PLC grew its position in BridgeBio Pharma by 268.2% in the fourth quarter. Barclays PLC now owns 1,201,885 shares of the company’s stock valued at $9,159,000 after acquiring an additional 875,468 shares during the last quarter. Institutional investors and hedge funds own 96.46% of the company’s stock.
About BridgeBio Pharma
BridgeBio Pharma, Inc engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
- Get a free copy of the StockNews.com research report on BridgeBio Pharma (BBIO)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.